Sort   by:  
 Page size 
ProteomicsInteractomic characterization of ESR1 mutant cells
Three quarters of all breast cancer cases express the estrogen receptor (ER, ESR1 gene), which promotes tumor growth and constitutes a direct target for endocrine therapies. ESR1 mutations have been implicated in therapy resistance in metastatic breast cancers, in particular to aromatase inhibitors....
ORGANISM(S): Homo sapiens (Human) 
2024-03-26 | PXD032404 | Pride
Esr1 mutation Breast cancer 
ProteomicsPhosphoproteome characterization of ESR1 mutated breast cancer cells
Three quarters of all breast cancer cases express the estrogen receptor (ER, ESR1 gene), which promotes tumor growth and constitutes a direct target for endocrine therapies. ESR1 mutations have been implicated in therapy resistance in metastatic breast cancers, in particular to aromatase inhibitors....
ORGANISM(S): Homo sapiens (Human) 
2024-03-26 | PXD032285 | Pride
Phosphoproteome Esr1 mutations Breast cancer 
TranscriptomicsXenografting of advanced stage breast cancer preserves the genomic and clonal architecture and captures luminal tumors harboring mutations and gene rearrangements in ESR1
End-stage breast cancers are clonally heterogeneous and harbor many poorly-understood treatment resistance mechanisms. We therefore established multiple Patient-Derived-Xenograft (PDX) models to study genomic events driving advanced disease. Comparative whole-genome sequencing of paired primary tu...
ORGANISM(S): Homo sapiens 
2013-12-22 | E-GEOD-46604 | biostudies-arrayexpress
ProteomicsProteomic characterization of ESR1 mutant cells
Three quarters of all breast cancer cases express the estrogen receptor (ER, ESR1 gene), which promotes tumor growth and constitutes a direct target for endocrine therapies. ESR1 mutations have been implicated in therapy resistance in metastatic breast cancers, in particular to aromatase inhibitors....
ORGANISM(S): Homo sapiens (Human) 
2024-03-26 | PXD032369 | Pride
Esr1 mutation Breast cancer 
ProteomicsProteomic and phosphoproteomic analysis of ESR1 mutant cells
Three quarters of all breast cancer cases express the estrogen receptor (ER, ESR1 gene), which promotes tumor growth and constitutes a direct target for endocrine therapies. ESR1 mutations have been implicated in therapy resistance in metastatic breast cancers, in particular to aromatase inhibitors....
ORGANISM(S): Homo sapiens (Human) 
2024-03-26 | PXD046446 | Pride
Breast cancer Human 
GenomicsRNAseq of cell lines with knocked in ESR1 mutations
RNAseq of cell lines with knocked in ESR1 mutations
PRJNA445373 | ENA
GenomicsActivating mutations in ESR1 contribute to an immunosuppressive breast tumor microenvironment.
Activating mutations in ESR1 contribute to an immunosuppressive breast tumor microenvironment.
PRJNA1276544 | ENA
GenomicsModeling the ESR1 tyrosine 537 mutation with CRISPR-Cas9 for mechanistic studies and evaluation of therapeutic approaches for metastatic breast cancer [ChIP-Seq]
Estrogen receptor-α (ERα) is an important driver of breast cancer and is the target for hormonal therapies, anti-estrogens and drugs that limit estrogen biosynthesis (aromatase inhibitors). Mutations in the ESR1 gene identified in metastatic breast cancer provide a potential mechanism for acquired...
ORGANISM(S): Homo sapiens 
2016-10-25 | E-GEOD-78284 | biostudies-arrayexpress
GenomicsESR1 Y537S and D538G mutations drive resistance to CDK4/6 inhibitors in estrogen receptor-positive breast cancer
ESR1 Y537S and D538G mutations drive resistance to CDK4/6 inhibitors in estrogen receptor-positive breast cancer
PRJNA1183347 | ENA
ProteomicsEstrogen Receptor Mutant Coregulator
Biotinylated 4xERE-containing DNA immobilized on streptavidin beads used to pulldown proteins recruited by unliganded WT ER-alpha versus Y537S, D538G, or ESR1-YAP1 fusion proteins from HeLa S3 human cell nuclear extracts.
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2017-02-08 | MSV000080536 | MassIVE
Sort   by:  
 Page size